Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Tasly Forges $22 Million Partnership with France's Pharnext

publication date: May 10, 2017
China's Tasly Pharma formed a partnership with Pharnext SA, a French company that combines and repositions approved drugs to develop innovative therapies. The agreement has three parts: Tasly will invest $22 million in Pharnext; the two companies will form a JV to develop new drugs using Pharnext's platform; and Tasly acquired China rights to Pharnext's lead drug candidate, a treatment for Charcot-Marie-Tooth disease type 1A. Tasly will contribute its knowledge of traditional Chinese medicines to the combination drug development JV. More details....

Stock Symbol: (SHA: 600535) (Paris: ALPHA)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital